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We employed antibody pre-conditioning with alem-
tuzumab and posttransplant immunosuppression 
with low-dose tacrolimus monotherapy in 26 consec-
utive pediatric kidney transplant recipients between 
January 2004 and December 2005. Mean recipient 
age was 10.7 ± 5.8 years, 7.7% were undergoing re-
transplantation, and 3.8% were sensitized, with a PRA 
>20%. Mean donor age was 32.8 ± 9.2 years. Living 
donors were utilized in 650/0 of the transplants. Mean 
cold ischemia time was 27.6 ± 6.4 h. The mean num-
ber of HLA mismatches was 3.3 ± 1.3. Mean follow-up 
was 25 ± 8 months. One and 2 year patient survival 
was 100% and 96%. One and 2 year graft survival was 
96% and 88%. Mean serum creatinine was 1.1 ± 0.6 
mg/dL, and calculated creatinine clearance was 82.3 
± 29.4 mL/min/1. 73 m2 • The incidence of pre-weaning 
acute rejection was 11.5%; the incidence of delayed 
graft function was 7.7%. Eighteen (69%) of the children 
were tapered to spaced tacrolimus monotherapy, 10.5 
± 2.2 months after transplantation. The incidence of 
CMV, PTLD and BK virus was 0%; the incidence of post-
transplant diabetes was 7.7%. Although more follow-
up is clearly needed, antibody pre-conditioning with 
alemtuzumab and tacrolimus monotherapy may be a 
safe and effective regimen in pediatric renal transplan-
tation. 
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In all transplant patients, but especially in pediatric recip-
ients, minimizing the side affects of immunosuppression 
is perhaps as important as improving patient and graft sur-
vival. In our pediatric kidney recipients, we have utilized an 
immunosuppressive regimen based on a novel paradigm, 
emphasizing recipient pre-conditioning with minimal post-
transplant immunosuppression (1-5). This regimen avoids 
posttransplant maintenance corticosteroids, which have 
had such deleterious effects on growth in children, and 
allows for low-dose tacrolimus monotherapy, to minimize 
nephrotoxicity. We recently reported on the early clinical 
experience with this regimen (4), and in this report de-
scribe a larger, more comprehensive experience with alem-
tuzumab pre-conditioning and tacrolimus monotherapy. 
Patients and Methods 
Recipient and donor demographics 
Between January 2004 and December 2005. 26 consecutive pediatric pa-
tients underwent kidney transplantation alone at the Children's Hospital of 
Pittsburgh. The mean recipient age was 10.7 ± 5.8 years (range 1-19). Two 
17.7%) patients were undergoing retransplantation, and one 13.8%) was 
sensitized, with a PRA >20%. The mean donor age was 32.8 ± 9.2 years 
(range 17-53), and 17 (65%) cases were with living donors. The mean cold 
ischemia time for the deceased donor cases was 27.6 ± 6.4 h and the mean 
number of HLA mismatches was 3.3 ± 1.3. 
Immunosuppression 
Immunosuppression was with alemtuzumab (6-1 0) 0.4-0.5 mg/kg. given as 
a single i.v. dose after induction of anesthesia over 2-3 h. Pre-medication 
was with i.v. methylprednisolone 10-20 mg/kg, famotidine, diphenhy-
dramine and acetaminophen. A second dose of i.v. methylprednisolone was 
given during the arterial anastomosis. On postoperative day one, tacrolimus 
monotherapy was started at a dose of 1-3 mg twice daily, with a target 
12 h trough of 10 ng/mL for the first 3.5-4 months after transplantation. In 
stable patients. twice daily tacrolimus was then consolidated to once daily 
tacrolimus, i.e. a patient on 2 mg twice daily would be converted to 3 or 
4 mg once daily. Four to eight months later, stable patients on once daily 
immunosuppression would be taken to every other day immunosuppres-
sion, i.e. a patient on 4 mg once a day would be converted to 4 mg every 
other day. Further spaced weaning was generally not undertaken. 
Rejections were generally biopsy proven, and were treated initially with 
steroids and an adjustment of the tacrolimus dosage. 
Immunologic monitoring 
Beginning in October 2004, routine serial monitoring for donor specific anti-
bodies (DSA) was undertaken. Patients on spaced weaning who developed 
evidence of DSA were returned to once daily tacrolimus. If necessary, my-
cophenolate mofetil was added several months later. In patients not yet on 
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spaced weaning who developed donor specific antibody, immunosuppres-
sion was generally increased, from once daily to twice daily tacrolimus, with 
or without the addition of mycophenolate mofetil. 
Institutional oversight (11) 
The Pharmacy and Therapeutics Committee made the determination that 
the use of alemtuzumab was considered to be innovative clinical therapy, 
and requested that patients' families sign consent prior to the administration 
of alemtuzumab. Thus, all patients undergoing kidney transplantation dur-
Ing this time frame signed consent to receive alemtuzumab. Subsequently, 
in February 2006, the Pharmacy and Therapeutics Committee made the 
determination that the regimen seemed to be associated with adequate 
safety, and decided that parents no longer needed to sign consent for alem-
tuzumab. Data analysis was carried out under an IRB-approved protocol. 
Strong and enthusiastiC institutional support remained in force throughout 
thiS time period. 
Results 
The mean follow-up was 25 ± 8 months. 
One year actual patient survival was 100%, and 2 year ac-
tuarial patient survival was 96%. One patient died at home 
of a presumed mucus plug 18 months after transplanta-
tion, with a serum creatinine of 0.5 mg/dL. He had had a 
complicated course after transplantation and had required 
a tracheostomy. At the time of his death, he was at home 
recovering from elective bowel surgery. One year actual 
graft survival was 96% and 2 year actuarial graft survival 
was 88%. Two kidneys were lost, in addition to the one 
death, one 11 months after transplantation to recurrent fo-
cal segmental glomerulosclerosis, and one 20 months after 
transplantation to torsion of an intra-abdominal kidney. 
Renal function 
At 3 months, the serum creatinine was 1.1 ± 0.6 mg/dL, 
and the calculated creatinine clearance was 82.3 ± 27.9 
mL/min/1.73 m2. At most recent follow-up, the serum cre-
atinine was 1.1 ± 0.6 mg/dL, with a calculated creatinine 
clearance of 82.6 ± 29.4 mL/min/1.73 m2 
Rejection 
Biopsy-proven acute rejection was demonstrated in four 
(11.5%) patients; in two of these patients, noncompliance 
(as admitted by the patients) was an important factor in 
the development of acute rejection. There were no cases 
of steroid resistant rejection. 
Delayed graft function 
Delayed graft function, defined as the need for dialysis in 
the first week after transplantation, was seen in two (7.7%) 
patients. Both patients ultimately recovered good kidney 
function. 
Viral complications/posttransplant diabetes mellitus 
(PTDM) 
There were no cases of cytomegalovirus disease, post-
transplant Iymphoproliferative disorder, or BK virus. Pro-
phylactic valganciclovir was administered for 6-12 months. 
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In the 15 (58%) CMV seropositive donor/seronegative re-
cipient cases, CMV antigenemia (and beginning in 2006, 
PCR) was monitored weekly for the first 4 months, monthly 
for the next 4 months and then every 2-3 months, and 
was transiently positive at a low level (6 cells /200 000) 
in 1 (7%) patient. Seroconversion was documented in 3 
of 13 (23%) cases, and was not assessed in 2 cases, 
both of whom remained antigenemia/PCR negative. In the 
14 (54%) EBV seropositive donor/seronegative recipient 
cases (this group received 12 months of valganciclovir pro-
phylaxis), EBV PCR's were monitored on monthly basis for 
the first year, and every 2-3 months thereafter, and were 
detectable in 2 (14%) cases, 1 transiently, and 1 at a low-
grade level (peak 1500, current 285). Seroconversion was 
documented in 4/13 (31 %) cases, and was not assessed 
in 2 cases, both of whom remained PCR negative. There 
were two (7.7%) cases of PTDM, one occurring in a re-
transplant recipient who had developed posttransplant di-
abetes after his first transplant, and another in a teenager 
with spina bifida who became morbidly obese prior to be-
coming insulin dependent. 
There was one (3.8%) case of autoimmune hemolytic ane-
mia. This patient received corticosteroids and had a reduc-
tion of the tacrolimus dosage from once daily to every other 
day, with resolution of the anemia and eventual discontin-
uation of corticosteroids. 
Spaced weaning 
Spaced weaning was attempted in 18 (69%) patients. At 
most recent follow-up, 12 (46%) patients were on spaced 
weaning. Weaning was started a mean of 10.5 ± 2.2 
months after transplantation. A total of 5 (19%) patients 
resumed once daily tacrolimus, because of the develop-
ment of DSA after spaced weaning. There were no patients 
who developed acute rejection on spaced weaning; there 
was one patient who had been taken back to once daily 
tacrolimus because of DSA, who developed an acute re-
jection episode related to noncompliance. He was treated 
with steroids and the addition of mycophenolate mofetil. 
The one other patient whose weaning was discontinued 
was the patient who lost her kidney to torsion. 
Growth (Figure 1) 
At the time of transplantation, the mean Z-score in height 
for age was -1.9 ± 1.9. After transplantation, catch up 
growth occurred as shown in Figure 1 and was most pro-
nounced for those in the lower rankings of the Z-score 
scale. At the time of most recent follow up, the mean rise 
in the Z-scores for height was 0.6 ± 0.9. In the group of 
recipients aged 10 or less at the time of transplantation, 
the mean increase in the height Z-score was 1.3 ± 0.8. 
Discussion 
This report builds on the early experience with antibody 
pre-conditioning and tacrolimus (1-5) monotherapy, and 
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Figure 1: Height for age and gender Z-scores after transplan-
tation for the 26 recipients. Reference population for Z-score cal-
culations from the 2000 Center for Disease Control United States 
Growth Charts available at www.cdc.gov/growthcharts_ 
continues to suggest that this regimen may be safe and ef-
fective in unselected pediatric kidney transplant recipients. 
Two year actuarial patient survival was 96%, and 2 year 
actuarial graft survival was 88%. The rate of early acute 
rejection was relatively low, and included two cases of re-
cipient noncompliance. The quality of kidney function re-
mained excellent. and there were no viral complications. A 
total of 46% of the patients were able to be tapered to and 
maintained on spaced weaning with tacrolimus monother-
apy. Although the follow-up was short, reasonable catch-up 
growth was observed in this cohort of patients who were 
not receiving steroids after transplantation. 
These results in our pediatric patients mirror the results 
that we have obtained in the adult renal transplant re-
cipients, and confirm that this seems to be a reason-
able regimen for recipients of all ages (1-3,5). There is a 
paucity of clinical experience elsewhere with alemtuzumab 
in pediatric renal transplant recipients, and most of the 
published experience is from the University of Wiscon-
sin (12,13). Their published case series of four patients 
(12) has recently been augmented by a report on 10 living 
donor kidney recipients given two doses of alemtuzumab, 
tacrolimus, and mycophenolate mofetil, with no steroids 
administered after transplantation (13). A 100% 1-year pa-
tient and graft survival was obtained, with no evidence of 
clinical acute rejection and two cases of sub-clinical acute 
rejection. These data confirm the fundamental safety and 
efficacy of alemtuzumab given at the time of transplanta-
tion. 
The important limitations of this report include both a rel-
atively short follow-up and the fact that it is a nonrandom-
ized trial. Thus, while the data are encouraging, additional 
follow-up will be required, and further accrual of patients 
will be needed to confirm these relatively favorable short-
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term outcomes. In the meantime, this regimen appears to 
be a reasonably effective and attractive one, with good pa-
tient acceptance, excellent patient and graft survival rates 
and good catch-up growth. 
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